United States v. Monty Ray Grow

977 F.3d 1310
CourtCourt of Appeals for the Eleventh Circuit
DecidedOctober 21, 2020
Docket18-11809
StatusPublished
Cited by14 cases

This text of 977 F.3d 1310 (United States v. Monty Ray Grow) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Monty Ray Grow, 977 F.3d 1310 (11th Cir. 2020).

Opinion

USCA11 Case: 18-11809 Date Filed: 10/21/2020 Page: 1 of 44

[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT ________________________

No. 18-11809 ________________________

D.C. Docket No. 1:16-cr-20893-FAM-1

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

MONTY RAY GROW,

Defendant-Appellant,

________________________

Appeal from the United States District Court for the Southern District of Florida ________________________

(October 21, 2020)

Before LUCK, ED CARNES, and MARCUS, Circuit Judges.

PER CURIAM: USCA11 Case: 18-11809 Date Filed: 10/21/2020 Page: 2 of 44

A jury convicted Monty Grow of conspiring to commit healthcare and wire

fraud, committing healthcare fraud, conspiring to receive and pay kickbacks,

receiving kickbacks, and money laundering. The district court sentenced him to 262

months’ imprisonment. Grow argues on appeal that his convictions must be reversed

because the evidence was insufficient on all counts, the district court’s instruction to

the jury on the third day of deliberations was coercive and prejudicial, and the district

court plainly erred in failing to instruct the jury on the elements of wire fraud. Grow

also argues that his twenty-year sentence for conspiracy to commit healthcare and

wire fraud must be reversed because it was more than the maximum sentence

allowed by the jury’s general verdict. After reviewing the record and the briefs, and

considering the parties’ oral arguments, we affirm Grow’s convictions but vacate his

twenty-year sentence for conspiracy to commit healthcare and wire fraud and

remand for further proceedings consistent with this opinion.

FACTUAL BACKGROUND

Grow played football in college and the National Football League. But his

football career was short-lived. He suffered a career-ending knee injury and retired

after playing professional football for only two years. Life then took Grow in a

different direction—he invested in real estate and a durable medical equipment

company—before he found himself marketing medical products for a variety of

companies.

2 USCA11 Case: 18-11809 Date Filed: 10/21/2020 Page: 3 of 44

In early 2014, Grow started working for InforMD Solutions, a company that

marketed compounded medications to doctors for a pharmacy. Compounded

medications are made by blending medically active and inactive ingredients into a

mixture. They are designed to serve the particular needs of a patient that would

otherwise be unmet by commercially available medications.

Grow worked for InforMD as an independent contractor and was paid only

commissions. Whenever a doctor prescribed a medication that Grow had

recommended, the doctor would fax the prescription to InforMD, which would then

credit the prescription to Grow’s account and forward it to the pharmacy to be filled.

Grow’s commissions were calculated using a “tiered multilevel structure,” which

meant that he was paid for his own referrals and any referrals made by

representatives he brought in, any representatives brought in by those

representatives, and so on down the pyramid. Grow found it difficult to market

compounded medications for InforMD because the doctors he approached often had

existing relationships with other marketers.

By October 2014, Grow left InforMD and formed his own marketing

company using a similar business model. He teamed up with a pharmacy, Patient

Care America, to market three of its compounded medications: a pain cream; a scar

cream; and a metabolic vitamin. He also brought over two sales representatives and

paid them using the same tiered commission structure. Unlike InforMD, however,

3 USCA11 Case: 18-11809 Date Filed: 10/21/2020 Page: 4 of 44

Grow’s company recruited patients instead of doctors and used telemedicine

companies to prescribe the creams and vitamins to patients.

As the head of operations, Grow “typically did not talk to patients.” Grow

was primarily responsible for helping and recruiting sales representatives, and his

representatives were responsible for soliciting recruits.1 After speaking with a

recruit, Grow’s representatives would fill out an intake form with basic information

about the recruit, including their name, the location of any scars and pain on their

body, and whether they wanted the metabolic vitamin. Depending on the

telemedicine company Grow used, representatives would also include either a

“suggestion” of what the doctor should prescribe or a prefilled prescription for the

doctor to do nothing more than sign.

Grow told his representatives to “always” use the prescription codes p-01 for

the pain cream and sc-01 for the scar cream because they “paid the highest

reimbursement from the insurance company.”2 Grow also told his representatives

to pick the largest size for each cream—360 grams—because it “paid the highest

1 We use the term “recruit” to refer to any Tricare eligible beneficiary solicited by Grow’s sales representatives to receive prescriptions for Grow’s pain creams, scar creams, or metabolic vitamins. 2 The code p-01 corresponded to a formulation designed to treat “general pain [and] inflammation.” The other pain formulations were designed to treat neuropathic pain and chronic pain. The code sc-01 corresponded to a transdermal formulation designed to treat “all scar[s].” The other scar formulations were gel based. 4 USCA11 Case: 18-11809 Date Filed: 10/21/2020 Page: 5 of 44

insurance payment” and would give them “the highest commission.” 3 And he said

to mark as many refills as possible (either three or six, depending on the telemedicine

company) because he and his representatives got “commissions on all the refills.”

After everything had been filled out, Grow would forward the materials to a

telemedicine company, which would arrange for a doctor to call the recruit. If the

telemedicine doctor couldn’t reach the recruit, the recruit’s file would be

“cancelled.” If the doctor got ahold of the recruit, the doctor would conduct a brief

consult—typically between five and seven minutes, but sometimes as short as three

minutes—and prescribe Patient Care’s creams and vitamins. Recruits would

“rarely” be rejected. For one of the two telemedicine companies Grow used, doctors

issued prescriptions to ninety-seven percent of recruits they spoke with. The

telemedicine companies charged Grow a “consult fee” each time one of their doctors

spoke with a recruit.

Once a doctor issued a prescription, the telemedicine company would fax it to

Grow. If the most expensive options had not been prescribed, Grow “would get

upset and get [the prescription] changed” by complaining to the telemedicine

company’s owner. When Grow was satisfied with a prescription, he would forward

it to Patient Care. Patient Care would then fill the prescription, mail the creams and

3 The creams came in four sizes: 120 grams, 180 grams, 240 grams, and 360 grams. All were considered to be a monthly supply. To use up the 360-gram cream in a month, a patient would need to apply the cream at least twelve times a day. 5 USCA11 Case: 18-11809 Date Filed: 10/21/2020 Page: 6 of 44

vitamins to the recruit, and submit a claim for reimbursement to the recruit’s

insurance company. Patient Care would also charge recruits a copay, but Grow told

recruits (and told his representatives to tell their recruits) that they didn’t need to pay

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Zsa Zsa Couch
Eleventh Circuit, 2025
United States v. Mark Murphy
Eleventh Circuit, 2024
United States v. John Gladden
78 F.4th 1232 (Eleventh Circuit, 2023)
United States v. Monty Ray Grow
Eleventh Circuit, 2023
United States v. Ivan Andre Scott
61 F.4th 855 (Eleventh Circuit, 2023)
United States v. Andrew E. Fisher
Eleventh Circuit, 2022
United States v. Geo Geovanni
Eleventh Circuit, 2022
United States v. Prat
S.D. Florida, 2022
United States v. Arman Abovyan
988 F.3d 1288 (Eleventh Circuit, 2021)

Cite This Page — Counsel Stack

Bluebook (online)
977 F.3d 1310, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-monty-ray-grow-ca11-2020.